ICL Israel Chemicals Ltd (ICL)
Official siteBASIC MATERIALS • AGRICULTURAL INPUTS • NYSE
Market Cap: $6.03B
Last updated: Nov 17, 2026 at 11:06 AM ET
ICL Israel Chemicals Ltd (ICL) Financials: Revenue, Profit and Cash Flow
ICL Israel Chemicals reported revenue of $7.15B for the fiscal year ended Dec 31, 2025, up 4.6% from the year before. That year, net income was $226.00M with a net margin of 3.2%, operating cash flow was $954.00M and free cash flow was $130.00M. The quarter ended Sep 30, 2026 had revenue of $1.91B and net income of $120.00M.
Revenue and Margins
The operating margin was 9.8% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $5.36B, a compound annual rate of 3.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $7.15B | +4.6% | 30.6% | 9.8% | 3.2% |
| Dec 2024 | $6.84B | -9.2% | 33.0% | 11.3% | 5.9% |
| Dec 2023 | $7.54B | -24.8% | 35.4% | 15.1% | 8.6% |
| Dec 2022 | $10.02B | +44.0% | 50.2% | 35.1% | 21.6% |
| Dec 2021 | $6.96B | +37.9% | 37.5% | 17.4% | 11.3% |
| Dec 2020 | $5.04B | -4.3% | 29.5% | 4.0% | 0.2% |
| Dec 2019 | $5.27B | -5.1% | 34.5% | 14.3% | 9.0% |
| Dec 2018 | $5.56B | +2.5% | 33.4% | 27.3% | 22.3% |
| Dec 2017 | $5.42B | +1.0% | 30.9% | 11.6% | 6.7% |
| Dec 2016 | $5.36B | N/A | 31.0% | -0.1% | -2.3% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 44.5% from the year before. In the quarter ended Sep 2026, net income rose 4.3% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $7.15B | $6.84B | $7.54B | $10.02B | $6.96B | $5.04B | $5.27B | $5.56B | $5.42B | $5.36B |
| Cost of revenue | $4.97B | $4.58B | $4.87B | $4.98B | $4.34B | $3.55B | $3.45B | $3.70B | $3.75B | $3.70B |
| Gross profit | $2.19B | $2.26B | $2.67B | $5.03B | $2.61B | $1.49B | $1.82B | $1.85B | $1.67B | $1.66B |
| Research and development | $70.00M | $69.00M | $71.00M | $68.00M | $64.00M | $54.00M | $50.00M | $55.00M | $55.00M | $73.00M |
| Operating income | $703.00M | $775.00M | $1.14B | $3.52B | $1.21B | $202.00M | $756.00M | $1.52B | $629.00M | -$3.00M |
| Net income | $226.00M | $407.00M | $647.00M | $2.16B | $783.00M | $11.00M | $475.00M | $1.24B | $364.00M | -$122.00M |
| EBITDA | $1.35B | $1.38B | $1.67B | $4.04B | $1.69B | $634.00M | $1.18B | $1.98B | $992.00M | $413.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.91B | $2.13B | $2.02B | $1.70B | $1.85B | $1.83B | $1.77B | $1.60B | $1.75B | $1.75B | $1.74B | $1.69B |
| Gross profit | $628.00M | $664.00M | $626.00M | $468.00M | $604.00M | $554.00M | $560.00M | $535.00M | $596.00M | $568.00M | $557.00M | $560.00M |
| Operating income | $230.00M | $267.00M | $235.00M | $99.00M | $230.00M | $189.00M | $185.00M | $147.00M | $214.00M | $211.00M | $203.00M | $149.00M |
| Net income | $120.00M | $137.00M | $126.00M | -$73.00M | $115.00M | $93.00M | $91.00M | $70.00M | $113.00M | $115.00M | $109.00M | $67.00M |
Balance Sheet
As of Dec 2025, total debt of $2.58B exceeded cash and equivalents by $2.29B.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $12.41B | $11.32B | $11.63B | $11.75B | $11.08B | $9.66B | $9.17B | $8.75B | $8.71B | $8.55B |
| Current assets | $4.16B | $3.59B | $4.03B | $4.55B | $3.91B | $2.84B | $2.68B | $2.76B | $2.73B | $2.57B |
| Cash and equivalents | $291.00M | $327.00M | $420.00M | $417.00M | $473.00M | $214.00M | $95.00M | $121.00M | $83.00M | $87.00M |
| Total liabilities | $6.17B | $5.33B | $5.59B | $6.04B | $6.34B | $5.58B | $5.11B | $4.83B | $5.78B | $5.89B |
| Short-term debt | $876.00M | $384.00M | $858.00M | $512.00M | $577.00M | $679.00M | $420.00M | $610.00M | $822.00M | $588.00M |
| Long-term debt | $1.70B | $1.72B | $1.63B | $2.31B | $2.44B | $2.09B | $2.18B | $1.81B | $2.39B | $2.80B |
| Shareholder equity | $5.98B | $5.72B | $5.77B | $5.46B | $4.53B | $3.93B | $3.92B | $3.78B | $2.86B | $2.57B |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $13.28B | $13.19B | $13.01B | $12.41B | $12.26B | $12.38B | $11.69B | $11.32B | $11.56B | $11.21B | $11.49B | $11.63B |
| Total liabilities | $6.75B | $6.75B | $6.68B | $6.17B | $5.88B | $6.11B | $5.57B | $5.33B | $5.42B | $5.22B | $5.44B | $5.59B |
| Cash and equivalents | $494.00M | $496.00M | $407.00M | $291.00M | $356.00M | $582.00M | $312.00M | $327.00M | $393.00M | $287.00M | $363.00M | $420.00M |
| Shareholder equity | $6.22B | $6.15B | $6.05B | $5.98B | $6.13B | $6.01B | $5.84B | $5.72B | $5.87B | $5.75B | $5.76B | $5.77B |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 13.6% of operating cash flow. Dividends came to 172.3% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $954.00M | $1.36B | $1.59B | $2.02B | $1.06B | $804.00M | $992.00M | $620.00M | $847.00M | $966.00M |
| Capital expenditures | $824.00M | $713.00M | $780.00M | $747.00M | $611.00M | $626.00M | $576.00M | $572.00M | $457.00M | $632.00M |
| Free cash flow | $130.00M | $650.00M | $815.00M | $1.28B | $454.00M | $178.00M | $416.00M | $48.00M | $390.00M | $334.00M |
| Dividends paid | $224.00M | $308.00M | $489.00M | $1.17B | $276.00M | $118.00M | $273.00M | $241.00M | $237.00M | $162.00M |
| Investing cash flow | -$930.00M | -$711.00M | -$863.00M | -$754.00M | -$579.00M | -$583.00M | -$525.00M | $331.00M | -$333.00M | -$800.00M |
| Financing cash flow | -$78.00M | -$724.00M | -$712.00M | -$1.30B | -$244.00M | -$105.00M | -$490.00M | -$894.00M | -$511.00M | -$239.00M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $256.00M | $290.00M | $180.00M | $300.79M | $308.00M | $269.00M | $165.00M | $415.55M | $408.00M | $316.00M | $292.00M | $415.00M |
| Capital expenditures | $190.00M | $197.00M | $135.00M | $275.84M | $180.00M | $202.00M | $190.00M | $268.66M | $159.00M | $142.00M | $145.00M | $255.00M |
| Free cash flow | $66.00M | $93.00M | $45.00M | $24.95M | $128.00M | $67.00M | -$25.00M | $146.89M | $249.00M | $174.00M | $147.00M | $160.00M |
Frequently Asked Questions About ICL
What is ICL Israel Chemicals' annual revenue?
ICL Israel Chemicals reported revenue of $7.15B for the fiscal year ended Dec 31, 2025.
How fast is ICL Israel Chemicals' revenue growing?
Revenue was up 4.6% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -10.6%.
Is ICL Israel Chemicals profitable?
Yes. ICL Israel Chemicals reported net income of $226.00M for the fiscal year ended Dec 31, 2025, with a net margin of 3.2%.
How much free cash flow does ICL generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $954.00M minus capital expenditures of $824.00M produced free cash flow of $130.00M.
How much debt does ICL Israel Chemicals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $1.70B, short-term debt of $876.00M and cash and equivalents of $291.00M.
ICL pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors